99mTc-labelled S-HYNIC certolizumab pegol in rheumatoid arthritis and spondyloarthritis patients : a biodistribution and dosimetry study by Lambert, Bieke et al.
ORIGINAL RESEARCH Open Access
99mTc-labelled S-HYNIC certolizumab pegol
in rheumatoid arthritis and spondyloarthritis
patients: a biodistribution and dosimetry
study
Bieke Lambert1*† , Philippe Carron2†, Yves D’Asseler1, Klaus Bacher3, Filip Van den Bosch2, Dirk Elewaut2,4,
Gust Verbruggen2, Rudi Beyaert4,5, Caroline Dumolyn6 and Filip De Vos6
Abstract
Background: Biologicals directed against tumour necrosis factor (TNF) have proven their efficacy in the treatment
of spondyloarthritis and rheumatoid arthritis. We present a radiolabelling method for certolizumab pegol (CZP), a
commercially available humanized Fab′-fragment directed against TNF. A biodistribution and dosimetry study was
conducted.
Tc-S-HYNIC CZP was synthesized. The in vitro TNF neutralizing activity was tested by exposing L929s-cells to various
concentrations 99mTc-S-HYNIC CZP and measuring TNF-induced cytotoxicity. For biodistribution and dosimetry, WB
images and blood and urine sampling were performed up to 24 h pi. Cumulative activities were estimated using
mono-exponential fitting, and organ doses were estimated using OLINDA/EXM. The effective dose was calculated
using the International Commission on Radiological Protection 103 recommendations. The uptake of the tracer in
the peripheral joints was assessed visually and semiquantitatively.
Results: In vitro tests showed blocking of TNF cytotoxicity by the 99mTc-S-HYNIC CZP formulation comparable to
the effect obtained with the unlabelled CZP with or without the HYNIC linker. We analysed eight patients with
rheumatoid arthritis or spondyloarthritis. The highest mean absorbed organ doses were recorded for kidneys,
spleen, and liver: 56 (SD 7), 34 (SD 6), and 33 (SD 7) μGy/MBq. The effective dose was 6.1 (SD 0.9) mSv for a mean
injected activity of 690 (SD 35) MBq. The urinary excretion was 15.1% (SD 8.1) of the IA at 22.5 h. Blood analysis
yielded a distribution half-life of 1.2 h (SD 1.5) and an elimination half-life of 26.9 h (SD 2.7). Visual analysis of the
scans revealed marked tracer accumulation in the clinically affected peripheral joints. In addition, there was a
statistically significant higher uptake of the tracer in the swollen joints (median uptake ratio compared to
background of 3.3 in rheumatoid arthritis and 2.4 in peripheral spondyloarthritis) compared to clinically negative
joints (respectively 1.3 and 1.6).
Conclusions: We present a radiolabelling technique for CZP, a Fab′-fragment directed against TNF and currently
used as a therapeutic agent in rheumatology. An effective dose of 6.1 mSv (SD 0.9) was estimated. We confirmed
the uptake of this new radiopharmaceutical in clinically affected peripheral joints.
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Background
Spondyloarthritis (SpA) and rheumatoid arthritis (RA)
affect approximately 2% of the population [1, 2]. A key
insight in the pathogenesis was the discovery of the im-
portant role played by proinflammatory cytokines such
as tumour necrosis factor (TNF) [3, 4]. Fifteen years ago,
treatment options have been revolutionized by the intro-
duction of ‘biological agents’, including monoclonal anti-
bodies blocking TNF. However, some patients do not or
only partially respond to TNF antagonism. This might
be attributable to lower levels of TNF expression, the in-
volvement of other proinflammatory cytokines and/or
the development of neutralizing antibodies against the
TNF blocking agent during treatment. Therefore, on an
individual patient level, proof of TNF expression in the
affected joints might be helpful to optimize biological
treatment directed against TNF.
Certolizumab pegol (CZP) is a Fab′ fragment derived
from a humanized monoclonal antibody directed against
membrane associated as well as soluble TNFα. It is com-
mercially available as Cimzia (UCB Celltech, Slough,
Berkshire, UK). In this manuscript, we describe the
procedure of radiolabelling CZP and report the in vitro
activity. Secondly, we document the biodistribution and
dosimetric profile of this new radiopharmaceutical. Fi-
nally, we correlated the uptake of radiolabelled CZP with
the findings on clinical examination in patients with per-
ipheral joint involvement.
Methods
Synthesis of 99mTc-S-HYNIC CZP
All preparations were carried out under aseptic condi-
tions working in a LAF IIa cabinet.
Derivatisation of CZP for injection with S-HYNIC
A 200-mg lyophilized CZP vial was reconstituted with
water for injection (B. Braun, Melsungen AG, Germany);
100, 50 and 25 mg CZP was transferred to a Slide-A-
Lyzer with cut-off of 10 kDa (Pierce Protein Research
Products, Thermo scientific, Rockford, IL, USA) and dia-
lyzed against 500 ml of a mixture of a Dulbecco’s
phosphate-buffered saline (Lonza, Verviers, Belgium)
and a self-prepared 0.9% m/v sodium chloride solution
(Riedel-deHaën, Seelze, Germany) in 1:2 v/v ratio. Dialy-
sis was maintained for 4 h at 2–8 °C, with the buffer
refreshed after 1.5 h. Subsequently, 0.5 ml of a 8.4% so-
dium hydrogen carbonate (Merck, Darmstadt, Germany)
solution was added to the solution followed by 10 5.0 μl
portions of 1.7, 0.86 and 0.43% m/v solution of S-
HYNIC (ABX GmbH, Radeberg, Germany) in dry
DMSO (Merck, Darmstadt, Germany) at a pace of 1 por-
tion/min [5]. This yielded an average of 2.8 S-HYNIC
groups per CZP. After 30 min incubation at room
temperature in the dark, the reaction was quenched by
adding 3.0 ml cooled 0.15 M acetate buffer pH 5.0
(Merck, Darmstadt, Germany). The unreacted S-HYNIC
was removed by dialyzing the reaction mixture in a
Slide-A-Lyzer (cutoff of 10 kDa) overnight at 2–8 °C
against 500 ml acetate buffer, which was refreshed after
1, 2 and 3 h. The solution was diluted to 40.0 ml with
0.15 M acetate buffer pH 5.0 and membrane filtered
(0.22 μm). Following dispensing into 1.0 ml portions, the
glass vials were stored at −80 or 2–8 °C for 3 months.
Three concentrations of CZP were obtained: 2.5, 1.25
and 0.625 mg of S-HYNIC-coupled CZP. Quality control
was done by determination of the protein concentration
(BCA protein reagent) and the p-NBA HYNIC assay to
measure the number of S-HYNIC bifunctional chelator
coupled to the protein.
Preparation of the co-ligand kit
A solution containing 4.66 mM tin(II) sulphate (Sigma
Aldrich, Steinheim, Germany) and 55.81 mM tricine
(Sigma Aldrich, Steinheim, Germany) dissolved in ultra-
pure sterile and pyrogen-free water was prepared.
Radiolabelling with 99mTc
Fifty-microliter co-ligand kit and 925 MBq (±10%) 99mTc
pertechnetate were consecutively added to the S-HYNIC
CZP vial (2.5, 1.25 and 0.625 mg). After 15-min incuba-
tion, physiological saline was added in order to obtain a
volume of 3 ml. Quality control was carried out by in-
stant thin layer chromatography (iTLC) with SilG as sta-
tionary phase and 0.9% NaCl solution as mobile phase.
For the clinical study, the 1.25 mg S-HYNIC CZP vials
stored at −80 °C were used and the radiochemical yield
needed to exceed 90%.
Stability study
The impact of aggregation on the chemical stability and
radiochemical yield during storage of the formulation at
three different concentrations (2.5, 1.25 and 0.625 mg)
was studied over a 3-month period. Aggregate formation
was assessed by size-exclusion HPLC (Agilent Zorbax Diol
guard column), 4 × 12.5 mm, in series with a GF450, 9.4 ×
250 mm and a GF250 size exclusion analytical column,
9.4 × 250 mm (Agilent Technologies, Diegem, Belgium).
The mobile phase was composed of a mixture of a
200 mM phosphate buffer pH 7.0 and ethanol 90:10 v/v
(1 ml/min, 30 min). Influence on the radiochemical in-
corporation of 99mTc was studied by iTLC as described
earlier. Analyses were performed after preparation, at
2 weeks, 1 month and 3 months post production.
In vitro activity of 99mTc-S-HYNIC CZP against TNF-
induced cytotoxicity
Murine fibrosarcoma TNF-sensitive L929s cells were
cultured for 24 h by seeding 20,000 cells/well in 96-well
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plates, incubated at 37 °C with 5% CO2. The culture
medium consisted of DMEM (GIBCO-BRL, 41965-062)
supplemented with 10% fetal calf serum, 400 μM
sodium-pyruvate (Sigma) and non-essential amino acids
(Lonza). The following day, 55 μl human TNF (6.8 ×
107 U/ml) produced by the Protein Service facility of
VIB (Ghent, Belgium) was added at various concentra-
tions (10 dilutions starting at 300 U/ml) to the test solu-
tions at room temperature. The following solutions of
antibodies directed against TNF were tested: CZP, S-
HYNIC CZP, 99mTc-S-HYNIC CZP and infliximab
(Remicade, Merck, Johnson & Johnson). Dilutions of
250, 50 and 10 ng/ml anti-TNF antibodies (55 μl) were
preincubated with the human TNF for 45 min, as well as
control samples without TNF blocking agents. Actino-
mycin D (Sigma, 1 mg/ml dissolved in absolute ethanol),
at a final concentration of 1 μg/ml was also added.
Twenty-four hours following the exposure to the test solu-
tions, TNF cytotoxicity was measured using the MTT-test
by adding 20 μl filter sterilized 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma, 5 mg/
ml). After 4 h, 80 μl stopping solution (10% SDS, 0.01 M
HCL) was added and the read out was performed by a
multichannel plate reader at a wavelength of 595 nm with
a reference at 655 nm. The percentage of cell survival was
estimated according to the formula below:
% cell survival = (absorbance treated cells − background) /
(average absorbance non treated cells− background)*100.
Patients
The study was conducted in accordance with the Helsinki
declaration and was approved by the ethical committee of
the Ghent University Hospital. All patients signed an in-
formed consent. Patient selection was limited to subjects
aged 18–70 years and meeting the ‘American College of
Rheumatology’ (ACR) criteria for RA [6] or the ‘Assess-
ment of SpondyloArthritis international Society’ (ASAS)
criteria for axial or peripheral SpA [7, 8]. Patients were
not allowed if they had previously been treated with CZP
or any other biological treatment. For more detailed infor-
mation on the clinical eligibility criteria, we refer to the
online detailed study protocol (EudraCT number: 2009-
017998-37, http://clinicaltrials.gov/show/NCT01590966).
Scan procedure, blood and urine sampling
All patients were scanned on the same double-headed
gamma camera (BrightView, Philips Healthcare, Best, the
Netherlands). First, an attenuation map was obtained from
a whole-body (WB) scan using a Cobalt-57 flood source.
Subsequently, the patient was injected IV with 10.6 MBq/
kg 99mTc-S-HYNIC CZP. The net IA was calculated fol-
lowing correction for rest activity in the syringe and exact
time of administration (Veenstra ionization chamber VIK-
202, Veenstra Instruments, the Netherlands). WB images
(15 cm/min, 1024 × 512 matrix, pixel size 2.80 mm) were
performed immediately following administration, at 1, 4–
6 and 24 h post-injection (pi). A standard activity of ap-
proximately 5 MBq 99mTc in an unshielded syringe was
always in the field of view for quantification purposes.
Static images (5 min, 256 × 256 matrix, pixel size
2.33 mm) of hands and feet were acquired immediately
following the first WB scan, at 4–6 and 24 h.
All visualized organs (heart, lungs, liver, spleen, kid-
neys), as well as regions of interest (ROIs) for the WB,
background and standard activity were delineated
manually on the four geometric mean images, generated
from the WB scans (Nuclear Diagnostics, Stockholm,
Sweden). For each organ, attenuation correction factors
were calculated based on measured conversion factors
on our camera from 57Co to 99mTc. These conversion
factors were derived from sequential attenuation scans
with a 99mTc flood source and a 57Co flood source in the
first patient. The activity measured in the urine collec-
tions between the scans was used to correct the esti-
mated activity in the WB compartment. Cumulated
activities in the WB and various organs were estimated
using mono-exponential fitting and converted to time
integrated activity coefficients to be processed by
OLINDA/EXM 1.1 software (Stabin M. Vanderbilt
University, Nashville) to estimate the absorbed organ
doses. The adult male and female mathematical refer-
ence phantoms were applied. A bladder voiding interval
of 4 h was included in the model. In OLINDA/EXM 1.1,
effective doses (ED60) were directly calculated using
ICRP 60 tissue weighting factors [9]. In order to account
for the recent ICRP 103 recommendations, the effective
dose was recalculated manually by combining the ICRP
103 tissue weighting factors and the organ doses from
the OLINDA/EXM 1.1 output (ED103) [10]. As some
organs contributing to ED103 are not listed in the
OLINDA/EXM 1.1, the sum of tissue-weighting factors
for the available target organs were calculated (0.913 for
men and 0.922 for women). In the ED103 calculation,
these factors were accounted for by scaling [11].
Urinary tracer excretion was measured in sequential
urine collections at 1, 4–6 and up to 24 h pi. Total vol-
umes were recorded. Blood sampling was performed im-
mediately following IV tracer injection from a vein in
the contralateral arm and subsequently at 1, 4–6 and at
24 h pi. 99mTc activity was measured in 2 ml blood and
urine samples in triplicate on a calibrated NaI(Tl) 3″ ×
3″ gamma well counter (Cobra II, PerkinElmer, USA).
The raw count data generated from the NaI(Tl) 3″ × 3″
detector were converted to kBq by a calibration curve.
The standard samples—in the same geometry as the
urine and blood samples—were prepared from a stock
solution which was measured in the same calibrated
dose calibrator (ionization chamber) used to measure
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the 99mTc-HYNIC CZP syringes. Results were decay cor-
rected and expressed as kBq/ml and as %IA.
To assess the tracer accumulation in the peripheral joints,
we scored each joint visually and semiquantitatively. The
latter was done by manually drawing ROIs around each
joint (Hermes, Nuclear Diagnostics, Sweden). For each in-
dividual scan, a background ROI was defined within the
field of view, e.g. left supraclavicular region on WB, right
forearm on static images of the wrists and hands, right dis-
tal tibia for the static images depicting the ankles and feet.
These results were compared with the findings on clinical
examination for each assessable joint. The nuclear medicine
physician reading the immunoscans and the clinician per-
forming the clinical examination were blinded to each
other’s observations. Groups were compared by Mann-
Whitney U test using IBM SPSSv21 software (NY, USA).
Results
Preparation of S-HYNIC CZP
After preparation, the 2.5-, 1.25- and 0.625-mg vials con-
tained respectively 105, 98.5 and 99.8% of the label claim
for the total amount of protein indicating that no protein
losses were observed during the different handling steps.
The results of the p-NBA S-HYNIC incorporation test
showed a respective ratio of S-HYNIC/CZP of 1.2, 1.5 and
2.0. No substantial losses were observed for the vials
stored at −80 °C. In contrast, all formulations of the vials
stored at 2–8 °C suffered from a decrease of the S-
HYNIC/CZP ratio <0.1 after 3 months of storage.
The influence of storage temperature on aggregation and
radiochemical yield
At −80 °C, no change in the amount of aggregation was
observed over time; nevertheless, the amount of aggrega-
tion (mean for the 3 formulations: 1.7%) was somewhat
higher compared to the CZP blank formulation (<0.5%).
At 2–8 °C, however, aggregation increased over time
with the highest amount (20%) of aggregation observed
for the 2.5 mg CZP formulation after 1 month of stor-
age. All formulations stored at-80 °C had radiochemical
yields >95%. For the storage at 2–8 °C, all radiochemical
yields were >95% except for the 2.5 mg formulation of
which the yield decreased to 55%.
In vitro testing of the specific TNF neutralizing activity of
the 99mTc-S-HYNIC CZP formulation
In the samples exposed to 99mTc-S-HYNIC CZP, the
cytotoxic activity of TNF was completely blocked at
doses as low as 10 ng/ml (Fig. 1). The TNF neutralizing
effect of the 99mTc-S-HYNIC CZP formulation was
Fig. 1 Cell survival of TNF sensitive L929s cells following exposure to 0–300 U/mL of human TNF solutions and preincubated with 250, 50 and
10 ng/ml 99mTc-S-HYNIC CZP. In the control experiment, the cells are exposed to TNF but no inhibitor (99mTc-S-HYNIC CZP) is added
Table 1 Effect on survival of TNF sensitive L929s cells following exposure to 300 U/ml human TNF and various test solutions of TNF
blocking agents in the presence of 1 μg/ml Actinomycin D
Mean % cell survival (SD)
Tested TNF blockers at 3 concentrations 99mTc-S-HYNIC CZP S-HYNIC CZP CZP Infliximab
Control (no TNF blocker) 0.0 (0.0) 0.0 (0.0) 0.0 (0.0) 0.0 (0.0)
250 ng/ml 109.1 (2.6) 111.9 (0.5) 81.8 (1.5) 81.1 (3.9)
50 ng/ml 113.8 (4.2) 111.0 (2.2) 96.1 (23.2) 57.4 (1.4)
10 ng/ml 115.2 (0.6) 88.5 (0.3) 56.6 (2.8) 5.2 (0.0)
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comparable to the effect obtained with the unlabelled
CZP with or without the HYNIC linker. Infliximab, an-
other TNF blocker that was used as a positive control,
also showed good neutralizing activity, although it was
less active at the doses used (Table 1).
Patient study
We analysed eight patients (four males and four females):
one RA patient, two peripheral SpA patients and five axial
SpA patients. The median age was 44 years (range 26–68).
A mean (standard deviation, SD) activity of 690 (SD 35,
range 665–728) MBq 99mTc-S-HYNIC CZP (1.07 mg, SD
0.04, range 1.01–1.10) was injected. There were no
Fig. 2 a WB images immediately (left), 5 h (middle) and 24 h (right)
pi of 706 MBq 99mTc-S-HYNIC CZP. b Static images (at 5 h pi) of the
hands in a female suffering axial SpA. This patient presented with
only radiographic axial involvement and had no signs of peripheral
articular involvement. No enhanced tracer uptake in peripheral joints
or the axial skeleton was noted
Fig. 3 Static images approximately 15 min (left) and 5 h (right) pi of
99mTc -S-HYNIC CZP in a patient suffering RA. A typical poly-articular
pattern in the hand joints without distal interphalangeal involvement
is observed
Fig. 4 Left: Static images in a man suffering psoriatic arthritis,
acquired approximately 5 h pi of 99mTc-S-HYNIC CZP. Uptake in the
metacarpophalangeal, proximal and distal interphalangeal joint of
the right second digit is observed, compatible with dactylitis. Right:
Tracer uptake 5 h pi in both the joints and the accompanying flexor
tendon in a female suffering psoriatic arthritis with clinically dactylitis
of the fourth left digit
Table 2 Summary of the organ doses, expressed per injected
MBq of 99mTc-labelled S-HYNIC CZP as well as for the total mean







Brain 1.3 0.5 0.9 0.3
Skin 1.8 0.3 1.2 0.2
Thyroid 2.1 0.4 1.4 0.3
Uterus 4.6 0.5 3.3 0.4
Ovaries 3.9 0.5 2.7 0.4
Testes 1.7 0.5 1.1 0.4
Breasts 3.7 0.5 2.5 0.4
Red marrow 3.8 0.4 2.6 0.3
Muscle 3.5 0.5 2.4 0.3
Small intestine 4.3 0.6 3.0 0.4
ULI wall 4.9 0.7 3.4 0.5
LLI wall 3.1 0.7 2.2 0.5
Stomach wall 6.3 1.0 4.3 0.7
Thymus 6.9 0.8 4.7 0.5
Osteogenic cells 7.4 1.4 5.1 1.0
Pancreas 10.8 1.6 7.4 1.1
Adrenals 11.2 1.7 7.7 1.2
Gallbladder wall 11.9 1.8 8.2 1.2
Lungs 18.6 2.7 12.8 1.9
Urinary bladder wall 19.9 8.3 13.7 5.8
Heart wall 30.6 5.1 21.1 3.5
Liver 32.7 6.9 22.5 4.7
Spleen 34.0 6.2 23.4 4.3
Kidneys 56.1 7.3 38.7 5.1
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adverse or clinically detectable pharmacologic effects in
any of the subjects.
On the WB images, we observed high tracer uptake in
the bloodpool and liver and less pronounced uptake in
the spleen and kidneys. WB scintigraphy and static im-
ages of the hands of a woman suffering axial SpA are
depicted in Fig. 2 and illustrate the ‘normal peripheral
distribution’ of 99mTc-S-HYNIC CZP. Patients with per-
ipheral joint involvement showed typical patterns on
immunoscintigraphy with a poly-articular pattern in RA
and involvement of the distal interphangeal joints,
dactylitis and tenosynovitis in psoriatic arthritis
(Figs. 3 and 4). The tracer uptake in the affected
joints persisted over time. In the patient with RA, 16
joints showed marked tracer accumulation and 4 of
these joints were clinically swollen. Out of the 50
negative joints on scintigraphy, all but 1 were also
negative on clinical examination for swelling. Semi-
quantitative analysis yielded a median uptake ratio in
swollen joints of 3.3 (range 0.6–7.5) vs 1.3 (range
0.8–5.0) in joints negative for swelling on clinical
examination (p < 0.001 Mann-Whitney U test). In the
2 patients with peripheral SpA, 29 joints were visually
scored positive on the immunoscan of which 20 joints
were swollen on clinical assessment. Amongst the 147
joints negative on scintigraphy, 144 were also clinically
classified as not swollen. Semiquantification yielded a me-
dian uptake ratio of swollen joints of 2.4 (range 1.0–6.3) vs.
1.6 (range 0.3–3.3) in non-swollen joints (p < 0.001 Mann-
Whitney U test).
According to our dosimetry study, the highest organ
doses were attributed to the kidneys, spleen and liver
with estimates of respectively 38.7 (SD 5.1) mGy, 23.4
(SD 4.3) mGy and 22.6 (SD 4.8) mGy or 56 (SD 7), 34
(SD 6) and 33 (SD 7) μGy/MBq. Table 2 summarizes our
findings for the various organs included in the analysis.
The estimated mean ED60 and ED103 were 8.93 (SD
1.14) μSv/MBq and 8.89 (SD 1.31) μSv/MBq, respect-
ively. Taking into account the administered activity of
690 (SD 35) MBq, a mean ED60 and ED103 of 6.2 (SD
0.9) mSv and 6.1 (SD 1.0) mSv is obtained. Figure 5
shows the average time-activity curves as a percentage
of the IA for the different organs. It can be observed
from this figure that the mono-exponential fit ad-
equately models the data. The urinary excretion was
15.1% (SD 8.1) of the IA at 22.5 h. The cumulative urin-
ary excretion is tabulated in Table 3. The blood clear-
ance shows a biphasic bi-exponential shape. Blood
samples were fitted to a two-compartment model by the
least square method. As illustrated in Fig. 6, a distribu-
tion half-life of 1.2 h (SD 1.5) and an elimination half-
life of 26.9 h (SD 2.7) were estimated.
Discussion
Based on large randomized controlled trials, there is evi-
dence for a therapeutic benefit of TNF blocking agents
Fig. 5 Average time-activity curves for the organs with the highest tracer uptake, as a percentage of the IA for the different organs, with standard
deviations and exponential fits
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in RA, axial SpA and psoriatic arthritis [12–14]. Several
TNF blockers have also proven their clinical value in
psoriasis and inflammatory bowel disease [15, 16]. Im-
aging studies utilizing these biological agents could offer
an individually tailored approach to pick the treatment
which targets the disease best. This is in the interest of
the patient who will not be exposed to unnecessary ther-
apies. It also represents a cost saving for society, since
these biologicals often involve substantial financial costs.
But besides these practical potential benefits, the im-
aging studies open a window on various pathophysio-
logical and pharmacokinetic aspects.
CZP differs from other TNF blockers because of its
link with polyethylene glycol [17–20]. This PEGylation
has been shown in animal studies to drive preferential
distribution to inflamed tissue over normal tissue to a
greater extent than observed with adalimumab and
infliximab [20].
In the past, only few attempts were made to visualize
TNF antagonists in patients [21]. So far, no radiolabel-
ling was reported for CZP.
In a first step, we confirmed that the in vitro TNF
neutralizing effect of the 99mTc-S-HYNIC CZP formula-
tion was comparable to the blocking effect observed for
the unlabelled S-HYNIC CZP and the non-conjugated
CZP. Considering the low ratio of radiolabelled S-
HYNIC CZP to cold S-HYNIC CZP in the samples ex-
posed to 99mTc-S-HYNIC CZP, this experiment cannot
serve as a direct proof of specific binding of 99mTc-S-
HYNIC CZP to TNF. However, the satisfying blocking
effects obtained with cold S-HYNIC CZP are a strong
indirect indication since it is rather the conjugation with
S-HYNIC that is expected to affect the TNF affinity ra-
ther that the addition of 99mTc.
In a second step, the conditions for derivatisation with
S-HYNIC, storage temperature and radiolabelling of
CZP were optimized. Optimal yields were obtained in
storage conditions at −80 °C. Under these conditions, no
cleavage of S-HYNIC from CZP was observed as indi-
cated by the molar ratio of incorporated S-HYNIC/CZP
which remained stable at 1.5 for the 1.25 mg CZP
formulation. The influence of mass was demonstrated
with approximately 20% of aggregates for the 2.5 mg
formulation. For these reasons, the 1.25 mg CZP for-
mulation stored at −80 °C was selected for the clin-
ical part of the study.
The presented clinical trial reports on the first in vivo
use of 99mTc-S-HYNIC CZP. WB images were acquired
and blood and urine samples were collected up to 24 h
pi in eight patients suffering from RA or SpA. The high-
est organ doses were recorded for kidneys, spleen and
liver. The effective dose was 6.1 mSv for a mean IA of
690 MBq. The obtained estimate for ED60 (8.9 μSv/
MBq) should be viewed in the light of other tracers, such
as 99mTc-labelled bisphosphonates (5.7 μSv/MBq) and
HIG (Human ImmunoglobulinesG) (7.0 μSv/MBq), which
are—despite their limited clinical value in this specific
context—often used in this patient population [22].
We observed marked tracer accumulation in the clin-
ically affected peripheral joints, which persisted at 24 h.
Barrera and coworkers published encouraging findings
Fig. 6 Clearance of radioactivity (kBq/ml) from the blood for all individual patients. The mean curve represents the calculated mean clearance
from the blood according to a two-compartment model. Activities are decay corrected to the time of injection. A distribution half-life of 1.2 h
(SD 1.5) and an elimination half-life of 26.9 h (SD 2.7) were estimated






1.5 h (0.3) 4.3% (2.1)
4.5 h (0.4) 8.5% (3.2)
22.5 h (1.4) 15.1% (8.1)
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with radiolabelled adalimumab in 10 patients with active
RA [23]. They radiolabelled this human anti-TNF mono-
cIonal IgG1 with 99mTc via S-HYNIC. They report uptake
in most of the affected joints, starting within minutes after
injection and persisting at 24 h. The accumulation of
tracer in clinically involved joints was often a factor 2
higher compared to the clinically unaffected joints, which
is concordant with our observations. However, in a clinical
context of increased vascularization and capillary perme-
ability, it is doubtful to attribute the 99mTc-S-HYNIC CZP
uptake predominantly to specific in vivo binding despite
the encouraging in vitro assay described above.
The presented study, mainly dealing with biodistribution
and dosimetry data from eight patients, was conducted in
the framework of a larger clinical trial [24]. In this trial, 20
patients underwent immunoscintigraphy with 99mTc-S-
HYNIC CZP and were subsequently treated with CZP for
24 weeks. The expected joint involvement patterns in both
peripheral and axial disease were detected by immunos-
cintigraphy with radiolabeled CZP: poly-articular pattern
in RA, distal interphangeal involvement and dactylitis in
psoriatic arthritis, and enthesitis and sacroiliitis in SpA.
The probability of a joint remaining tender despite
24 weeks of CZP treatment was significantly smaller in
joints with clear tracer uptake as compared to those with-
out on baseline immunoscintigraphy.
No adverse events were recorded following injection
of 99mTc-S-HYNIC CZP. No clinical effect on disease ac-
tivity was observed within a timeframe of 2 weeks after
the scintigraphic procedure. This was within our expec-
tations, since subtherapeutic doses of CZP were used for
the imaging study.
Conclusions
We present a radiolabeling technique for CZP, a bio-
logical agent, directed against TNF and currently indi-
cated for treatment of moderate to severe RA, axial SpA
and psoriatic arthritis. Following injection of 690 MBq
99mTc-S-HYNIC CZP in eight patients, an ED103 of 6.1
(SD 0.9) mSv or 8.9 (SD 1) μSv/MBq was estimated.
Urinary excretion was 15.1% of the IA at 22.5 h pi. The
distribution and elimination half-life in blood was esti-
mated to be respectively 1.2 (SD 1.5) and 26.9 h (SD
2.7). We obtained good accumulation of the tracer in
the clinically affected peripheral joints of patients suffer-
ing from active RA or peripheral SpA.
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